Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Quantum-Si incorporated (QSIAW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: QSIAW (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -79.85% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.44B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2.91 | 52 Weeks Range 0.05 - 2.23 | Updated Date 06/7/2025 |
52 Weeks Range 0.05 - 2.23 | Updated Date 06/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2982.42% |
Management Effectiveness
Return on Assets (TTM) -25.22% | Return on Equity (TTM) -40.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 146748948 |
Shares Outstanding - | Shares Floating 146748948 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Quantum-Si incorporated
Company Overview
History and Background
Quantum-Si incorporated was founded in 2013 with the goal of democratizing access to protein sequencing. The company developed a semiconductor chip-based platform for single-molecule protein sequencing.
Core Business Areas
- Protein Sequencing: Develops and commercializes a next-generation protein sequencing platform based on semiconductor chip technology.
Leadership and Structure
Dr. Jonathan Rothberg is the founder and chairman. The company has a typical C-suite structure with a CEO, CFO, and other functional VPs.
Top Products and Market Share
Key Offerings
- Platinum Protein Sequencing Platform: A semiconductor-based protein sequencing platform. The platform uses a proprietary detection method that enables simultaneous and direct detection of individual amino acids, with no reliance on antibodies, labels or amplification. Competitors include Roche, Thermo Fisher, and Pacific Biosciences. Market share data is not publicly available for this specific platform. Revenue from this product is not publicly available but it is the core offering.
Market Dynamics
Industry Overview
The protein sequencing market is growing, driven by increasing demand for proteomics research and drug discovery. Next-generation sequencing technologies are playing a growing role. The size of this market is in the billions of dollars and it is expected to see continued growth in the coming years.
Positioning
Quantum-Si is positioned as a disruptor in the protein sequencing market with its semiconductor-based approach, aiming for lower cost and increased accessibility. Competitive advantage: lower cost, higher scale.
Total Addressable Market (TAM)
The TAM for protein sequencing is estimated to be in the billions of dollars. Quantum-Si's positioning with the Platinum platform is targeted towards capturing a significant share of this TAM by offering a cost-effective and scalable solution.
Upturn SWOT Analysis
Strengths
- Novel semiconductor-based technology
- Potential for lower cost protein sequencing
- Experienced leadership team
- Strong IP portfolio
Weaknesses
- Limited commercial track record
- Reliance on single product platform
- Intense competition
- Cash Burn Rate
Opportunities
- Expanding proteomics research market
- Partnerships with pharmaceutical companies
- Development of new applications for protein sequencing
- Expanding platform applications
Threats
- Competition from established players
- Technological obsolescence
- Regulatory hurdles
- Economic downturn affecting research funding
Competitors and Market Share
Key Competitors
- TMO
- ILMN
- PACB
- RHHBY
Competitive Landscape
Quantum-Si is a small player in the market compared to established giants. Quantum-Si's advantage lies in its technology. Disadvantage includes: smaller market presence, commercial track record.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth due to early stage of commercialization.
Future Projections: Analyst estimates are not available. Future growth relies on successful commercialization of the Platinum platform.
Recent Initiatives: Focusing on scaling production, establishing distribution channels and forging partnerships.
Summary
Quantum-Si is an early-stage company with a novel technology in the growing protein sequencing market. Its semiconductor-based platform offers the potential for lower cost and increased scalability. However, the company faces intense competition from established players and needs to prove its commercial viability. Continued development of strategic initiatives will be crucial for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Industry reports
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quantum-Si incorporated
Exchange NASDAQ | Headquaters Branford, CT, United States | ||
IPO Launch date 2021-06-11 | President, CEO & Director Mr. Jeffrey Alan Hawkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.quantum-si.com |
Full time employees 149 | Website https://www.quantum-si.com | ||
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company offers Platinum NGPS instrument that provides single molecule amino acid level resolution with a streamlined workflow, including automated data analysis that accessible to researchers in all laboratory types; Platinum Pro NGPS instrument, a single molecule amino acid resolution, which provides an enhanced user interface, cloud or on instrument data analysis and an available pro mode; Library preparation kits to prepare protein sample for sequencing; Barcoding Kits to optimize the workflow and performance of technology; and Sequencing Kits contains the reagents and consumables used to perform NGPS on the Platinum or Platinum Pro instrument. It also provides Platinum Analysis Software, a cloud-based solution that automates data analysis workflows and provides a user-friendly interface and visualization of the sequencing results. Its products are used in antibody characterization, biomarker identification, protein identification, protein variants, protein barcoding, and post translational modification analysis applications. Quantum-Si incorporated was founded in 2013 is headquartered in Branford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.